Published Date: 08 Mar 2023
Results from the RESCUE BT2 trial showed that among patients with mild or major strokes, more patients taking tirofiban had better 90-day outcomes than aspirin.
Read Full NewsWomen living in parts of the United States with lower air quality, especially neighborhoods with heavy emissions from motor vehicles, are more likely to develop breast cancer, according to a multiyear analysis involving more ...
In a study of more than 100,000 screening mammograms, researchers demonstrated the potential of an AI tool to help identify women at higher risk of developing interval breast cancer, which is breast cancer that is diagnosed ...
Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class of therapeutics called antibody drug conjugates (ADCs). These treatments pair an antibody that targets ...
1.
The amount of liver tissue removed during gallbladder surgery has no discernible impact on overall survival.
2.
Research exposes far-reaching toll of financial hardship on patients with cancer
3.
According to research, the mineralization of the bone matrix controls the growth of tumor cells.
4.
Treatment of Smoldering Myeloma Cuts Progression Rate in Half
5.
Patient Endured 9 Years of Chemotherapy for Cancer He Never Had
1.
Unlocking the Mystery of Glanzmann Thrombasthenia: A New Hope for Patients
2.
Hope in Numbers: Understanding AML Leukemia Survival Rates and Emerging Therapies
3.
A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies
4.
The Mysterious Pain of Scrotal Hematoma: A Guide to Diagnosis and Treatment
5.
Polycythemia Vera: A Historical Perspective and Contemporary Management
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- The Incidence of Cancer in Men
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
5.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation